Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

LSCN and TCG Form Collaboration

Published: Monday, June 03, 2013
Last Updated: Monday, June 03, 2013
Bookmark and Share
News attracts medical device, diagnostic and biotechnology companies interested in US or European market expansion.

LSCN Ltd. and the Technology Commercialization Group (TCG) have created an international strategic partnership to help life science companies with transatlantic business development and corporate development projects.

“We’re delighted to be working with LSCN, a premier European life sciences consulting firm”, said Ken West, Managing Partner of TCG.

West continued, “They have the skills, local experience and ‘on-the-ground’ presence necessary to help our US-based clients develop and implement European market entry and growth strategies”.

The US and Europe are the two largest life science, medical device, biotech and pharmaceutical markets in the world, but they have vastly different regulatory, reimbursement, marketing and legal environments.

Life science companies who have developed and marketed a product on one continent often find that developing business across the Atlantic is a challenge. This is especially true for emerging and mid-sized companies.

Dr. Alrik Koppenhöfer, Managing Director & Partner of LSCN, commented “Many European companies aim to internationalize their business, especially in the US marketplace, but are concerned about the FDA, US lawyers and the resources necessary to effectively compete. TCG has guided many European companies in entering or expanding in the US, so they know what works well. Vice versa, LSCN supports many companies in Europe’s multi-cultural and diverse legal and business environment to implement customized solutions”.

In addition to providing services for transatlantic corporate development and growth, both LSCN and TCG provide specialized life science product development oversight as well as interim management for corporate expansion efforts.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos